002773 康弘药业
已收盘 08-03 15:00:00
资讯
新帖
简况
股市必读：康弘药业新发布《关于公司参与全国药品集中采购拟中选的公告》
证券之星 · 02:24
股市必读：康弘药业新发布《关于公司参与全国药品集中采购拟中选的公告》
康弘药业最新公告：吡仑帕奈片拟中选第12批国家药品集采
证券之星 · 08-02 16:21
康弘药业最新公告：吡仑帕奈片拟中选第12批国家药品集采
股市必读：康弘药业（002773）新发布《关于董事会延期换届的公告》
证券之星 · 07-31
股市必读：康弘药业（002773）新发布《关于董事会延期换届的公告》
康弘药业（002773）披露董事会延期换届公告，7月29日股价上涨1.55%
证券之星 · 07-29
康弘药业（002773）披露董事会延期换届公告，7月29日股价上涨1.55%
康弘药业（002773）新增【AI医疗】概念
证券之星 · 07-28
康弘药业（002773）新增【AI医疗】概念
康弘药业新提交“利迈宁”商标注册申请
证券之星 · 07-28
康弘药业新提交“利迈宁”商标注册申请
康弘药业最新公告：子公司KHN921注射液获临床试验批准
证券之星 · 07-23
康弘药业最新公告：子公司KHN921注射液获临床试验批准
7月17日康弘药业跌6.49%，大成睿享混合A基金重仓该股
证券之星 · 07-17
7月17日康弘药业跌6.49%，大成睿享混合A基金重仓该股
康弘药业最新公告：13个产品纳入《国家基本药物目录(2026年版)》
证券之星 · 07-09
康弘药业最新公告：13个产品纳入《国家基本药物目录(2026年版)》
康弘药业：共13个主要在销产品纳入《国家基本药物目录(2026年版)》
格隆汇 · 07-09
康弘药业：共13个主要在销产品纳入《国家基本药物目录(2026年版)》
7月1日康弘药业涨8.07%，大成睿享混合A基金重仓该股
证券之星 · 07-01
7月1日康弘药业涨8.07%，大成睿享混合A基金重仓该股
股市必读：康弘药业（002773）6月30日董秘有最新回复
证券之星 · 07-01
股市必读：康弘药业（002773）6月30日董秘有最新回复
康弘药业：KH110处于临床III期阶段
证券之星 · 06-30
康弘药业：KH110处于临床III期阶段
6月29日康弘药业涨7.28%，大成睿享混合A基金重仓该股
证券之星 · 06-29
6月29日康弘药业涨7.28%，大成睿享混合A基金重仓该股
股市必读：康弘药业（002773）6月16日董秘有最新回复
证券之星 · 06-17
股市必读：康弘药业（002773）6月16日董秘有最新回复
康弘药业（002773）披露注销2023年股票增值权激励计划部分股票增值权公告，6月3日股价上涨1.08%
证券之星 · 06-03
康弘药业（002773）披露注销2023年股票增值权激励计划部分股票增值权公告，6月3日股价上涨1.08%
康弘药业（002773）披露二〇二五年度权益分派实施公告，6月1日股价上涨1.19%
证券之星 · 06-01
康弘药业（002773）披露二〇二五年度权益分派实施公告，6月1日股价上涨1.19%
康弘药业：KH815项目处于临床Ⅰ期阶段
证券之星 · 06-01
康弘药业：KH815项目处于临床Ⅰ期阶段
康弘药业：KH631、KH658已完Ⅱ期和Ⅰ期入组
证券之星 · 05-28
康弘药业：KH631、KH658已完Ⅱ期和Ⅰ期入组
康弘药业（002773）披露二〇二五年度股东会决议公告，5月22日股价下跌1.35%
中金财经 · 05-22
康弘药业（002773）披露二〇二五年度股东会决议公告，5月22日股价下跌1.35%
加载更多
公司概况
公司名称：
成都康弘药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2015-06-26
主营业务：
成都康弘药业集团股份有限公司的主营业务是药品（包括生物制品、中成药、化学药）和医疗器械（主要是眼科医疗器械）的研发、生产与销售。公司的主要产品是中成药、化学药、生物药、医疗器械。公司2025年荣获“环保诚信企业”和“无废工厂”称号。
发行价格：
13.62
{"stockData":{"symbol":"002773","market":"SZ","secType":"STK","nameCN":"康弘药业","latestPrice":21.68,"timestamp":1785740622000,"preClose":21.54,"halted":0,"volume":4013253,"delay":0,"changeRate":0.0065,"floatShares":687000000,"shares":921000000,"eps":1.1619,"marketStatus":"已收盘","change":0.14,"latestTime":"08-03 15:00:00","open":21.54,"high":21.77,"low":21.5,"amount":86870500,"amplitude":0.0125,"askPrice":21.68,"askSize":23,"bidPrice":21.67,"bidSize":96,"shortable":0,"etf":0,"ttmEps":1.1619,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785807000000},"marketStatusCode":5,"adr":0,"adjPreClose":21.54,"symbolType":"stock","openAndCloseTimeList":[[1785720600000,1785727800000],[1785733200000,1785740400000]],"highLimit":23.69,"lowLimit":19.39,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921326354,"isCdr":false,"pbRate":2.07,"roa":"--","peRate":18.659093,"roe":"3.25%","epsLYR":1.26,"committee":-0.335621,"marketValue":19974000000,"turnoverRate":0.0058,"status":0,"floatMarketCap":14889000000},"requestUrl":"/m/hq/s/002773/","defaultTab":"news","newsList":[{"id":"2656634337","title":"股市必读：康弘药业新发布《关于公司参与全国药品集中采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656634337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656634337?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:24","pubTimestamp":1785695052,"startTime":"0","endTime":"0","summary":"公司公告汇总关于公司参与全国药品集中采购拟中选的公告2026年7月31日，国家组织药品联合采购办公室发布《第12批国家组织药品集中带量采购拟中选结果公示》，成都康弘药业集团股份有限公司的吡仑帕奈片拟中选。采购周期至2029年12月31日，医疗机构将优先使用并确保完成约定采购量。公司于2026年5月取得该药品注册证书，拟中选将有助于扩大销售规模、提升市场占有率和品牌影响力。后续合同签订及市场销售存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU2148510915.USD","BK0239","LU1064131003.USD","LU1064130708.USD","BK0197","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656312742","title":"康弘药业最新公告：吡仑帕奈片拟中选第12批国家药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2656312742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656312742?lang=zh_cn&edition=full","pubTime":"2026-08-02 16:21","pubTimestamp":1785658876,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称，公司产品吡仑帕奈片拟中选第12批国家组织药品集中带量采购。该药品适用于成人和4岁及以上儿童癫痫部分性发作等治疗。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200006699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1064130708.USD","BK0197","BK0196","LU2148510915.USD","002773","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655280701","title":"股市必读：康弘药业（002773）新发布《关于董事会延期换届的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655280701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655280701?lang=zh_cn&edition=full","pubTime":"2026-07-31 02:09","pubTimestamp":1785434953,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，康弘药业报收于21.46元，下跌0.83%，换手率0.81%，成交量5.58万手，成交额1.21亿元。公司公告汇总关于董事会延期换届的公告成都康弘药业集团股份有限公司第八届董事会任期将于2026年8月3日届满，因换届工作仍在筹备中，董事会换届选举将延期，董事会各专门委员会及高级管理人员任期相应顺延。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0239","BK0196","BK0197","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655899007","title":"康弘药业（002773）披露董事会延期换届公告，7月29日股价上涨1.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655899007","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655899007?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:39","pubTimestamp":1785335954,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，康弘药业报收于21.64元，较前一交易日上涨1.55%，最新总市值为199.38亿元。该股当日开盘21.32元，最高21.88元，最低21.32元，成交额达1.44亿元，换手率为0.97%。近日，康弘药业披露《关于董事会延期换届的公告》。在新一届董事会选举完成前，现任董事会成员及高管将继续履行职责。本次延期不会影响公司正常运营，公司将尽快推进换届工作并及时披露相关信息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900040740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0196","BK0197","BK0239","LU2148510915.USD","002773","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654400401","title":"康弘药业（002773）新增【AI医疗】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2654400401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654400401?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:30","pubTimestamp":1785241821,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，7月28日康弘药业新增概念。康弘药业主营业务：药品和医疗器械的研发、生产与销售。康弘药业2026年一季报显示，一季度公司主营收入10.46亿元，同比下降12.7%；归母净利润3.07亿元，同比下降23.13%；扣非净利润3.05亿元，同比下降21.97%；负债率6.18%，投资收益-21.48万元，财务费用-1234.46万元，毛利率88.66%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800036917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0239","BK0196","BK0197","002773","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654029861","title":"康弘药业新提交“利迈宁”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2654029861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654029861?lang=zh_cn&edition=full","pubTime":"2026-07-28 07:22","pubTimestamp":1785194538,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日成都康弘药业集团股份有限公司新提交“利迈宁”商标注册申请。商标申请详情如下：今年以来成都康弘药业集团股份有限公司新申请注册商标37件，截止目前公司共持有注册商标842件，另有132件商标尚在注册申请中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800005290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0196","BK0239","LU1064131003.USD","BK0197","LU1064130708.USD","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653746988","title":"康弘药业最新公告：子公司KHN921注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2653746988","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653746988?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:05","pubTimestamp":1784801102,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称，公司子公司成都弘基生物科技有限公司收到国家药监局签发的《药物临床试验批准通知书》，同意KHN921注射液开展用于治疗因MYBPC3突变所致肥厚型心肌病的临床试验。该产品为自主研发的AAV基因治疗药物，此前已于2026年4月获美国FDA准许在美国开展临床试验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300037296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0239","BK0196","BK0197","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652698406","title":"7月17日康弘药业跌6.49%，大成睿享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652698406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652698406?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:45","pubTimestamp":1784277939,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日康弘药业跌6.49%，收盘报22.04元，换手率1.84%，成交量12.62万手，成交额2.83亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为大成基金的大成睿享混合A。大成睿享混合A目前规模为44.23亿元，最新净值1.751，较上一交易日上涨0.54%，近一年上涨6.49%。大成睿享混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0197","002773","LU2148510915.USD","LU1064130708.USD","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650215149","title":"康弘药业最新公告：13个产品纳入《国家基本药物目录(2026年版)》","url":"https://stock-news.laohu8.com/highlight/detail?id=2650215149","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650215149?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:00","pubTimestamp":1783598417,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称，公司及子公司共13个主要在销产品纳入《国家基本药物目录(2026年版)》，包括康柏西普眼用注射液预充式、舒肝解郁胶囊、右佐匹克隆片、枸橼酸托法替布缓释片等4个新增产品。新版目录自2026年9月1日起施行，有利于产品在各级医疗机构推广使用，但对当期经营业绩影响暂无法准确估计。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900038356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0196","LU1064131003.USD","BK0197","002773","LU2148510915.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650475929","title":"康弘药业：共13个主要在销产品纳入《国家基本药物目录(2026年版)》","url":"https://stock-news.laohu8.com/highlight/detail?id=2650475929","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650475929?lang=zh_cn&edition=full","pubTime":"2026-07-09 19:53","pubTimestamp":1783597999,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0197","LU1064130708.USD","BK0239","LU1064131003.USD","LU2148510915.USD","BK0196","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516564","title":"7月1日康弘药业涨8.07%，大成睿享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648516564?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:48","pubTimestamp":1782895732,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日康弘药业涨8.07%，收盘报22.1元，换手率2.86%，成交量19.65万手，成交额4.19亿元。重仓康弘药业的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为大成基金的大成睿享混合A。大成睿享混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","LU1064131003.USD","LU2148510915.USD","BK0197","002773","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648565153","title":"股市必读：康弘药业（002773）6月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648565153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648565153?lang=zh_cn&edition=full","pubTime":"2026-07-01 01:39","pubTimestamp":1782841150,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，康弘药业报收于20.45元，下跌2.29%，换手率1.64%，成交量11.25万手，成交额2.29亿元。董秘最新回复投资者： 公司的阿兹海默症治疗药物KH110进展如何了，基因治疗在手订单充足吗董秘： 尊敬的投资者，您好！截至目前，中成药板块的KH110处于临床III期阶段。当日关注点交易信息汇总：6月30日主力资金净流入2502.91万元，散户资金净流出2525.86万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100000942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","LU1064131003.USD","BK0196","002773","LU1064130708.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581955","title":"康弘药业：KH110处于临床III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581955","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647581955?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:37","pubTimestamp":1782790621,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的阿兹海默症治疗药物KH110进展如何了，基因治疗在手订单充足吗康弘药业回复：尊敬的投资者，您好！截至目前，中成药板块的KH110处于临床III期阶段。基因治疗板块的KH631眼用注射液处于中国临床II期阶段、美国临床I期阶段；KH658眼用注射液处于中国临床II期阶段、美国临床I期阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000018207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","LU2148510915.USD","BK0239","BK0196","BK0197","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647380322","title":"6月29日康弘药业涨7.28%，大成睿享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647380322","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647380322?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:43","pubTimestamp":1782722613,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日康弘药业涨7.28%，收盘报20.93元，换手率2.25%，成交量15.45万手，成交额3.16亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为大成基金的大成睿享混合A。大成睿享混合A目前规模为44.23亿元，最新净值1.6434，较上一交易日下跌1.52%，近一年上涨2.45%。大成睿享混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","002773","LU1064130708.USD","LU2148510915.USD","BK0197","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644376234","title":"股市必读：康弘药业（002773）6月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644376234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644376234?lang=zh_cn&edition=full","pubTime":"2026-06-17 02:53","pubTimestamp":1781635990,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，康弘药业报收于20.1元，下跌2.28%，换手率0.83%，成交量5.67万手，成交额1.14亿元。当日关注点交易信息汇总：6月16日主力资金净流出665.01万元，游资资金净流入1043.05万元。公司公告汇总关于使用自有资金购买理财产品的公告康弘药业及子公司使用闲置自有资金购买理财产品，总额度不超过38亿元，期限为股东会审议通过之日起一年，资金可滚动使用。截至公告日，累计未到期理财产品金额为29.19亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700001124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0196","002773","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640990846","title":"康弘药业（002773）披露注销2023年股票增值权激励计划部分股票增值权公告，6月3日股价上涨1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640990846","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640990846?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:42","pubTimestamp":1780479770,"startTime":"0","endTime":"0","summary":"截至2026年6月3日收盘，康弘药业报收于21.56元，较前一交易日上涨1.08%，最新总市值为198.64亿元。公告显示，公司于2026年6月2日召开第八届董事会第十九次会议，审议通过《关于注销2023年股票增值权激励计划部分股票增值权的议案》。因公司2023年股票增值权激励计划第二个行权期业绩考核条件未达成，即2025年净利润增长率低于10%，不符合行权条件，公司决定对1名激励对象已获授但尚未行权的30,000份股票增值权进行注销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300036062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","LU1064130708.USD","LU2148510915.USD","BK0196","LU1064131003.USD","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995830","title":"康弘药业（002773）披露二〇二五年度权益分派实施公告，6月1日股价上涨1.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995830","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640995830?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:55","pubTimestamp":1780307704,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，康弘药业报收于21.25元，较前一交易日上涨1.19%，最新总市值为195.78亿元。该股当日开盘21.15元，最高21.35元，最低20.95元，成交额达1.32亿元，换手率为0.91%。公司于近日披露《二〇二五年度权益分派实施公告》。公告显示，成都康弘药业集团股份有限公司以现有总股本921,326,354股为基数，向全体股东每10股派发现金红利7.00元（含税），共计派发现金红利644,928,447.80元（含税）。本次权益分派实施后，股票期权行权价格将按规定进行调整。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100028117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0196","002773","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640642939","title":"康弘药业：KH815项目处于临床Ⅰ期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2640642939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640642939?lang=zh_cn&edition=full","pubTime":"2026-06-01 15:07","pubTimestamp":1780297635,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业06月01日在投资者关系平台上答复投资者关心的问题。投资者提问：5月29日至6月2日，2026年美国临床肿瘤学会年会即将于美国芝加哥举行，此前公司在今年4月23日举行的投资者关系活动中明确表示，将在2026年ASCO年会期间为KH815项目安排闭门会议进行交流。请问公司会在闭门会议当中会公布哪些关于KH815项目的临床数据，会以公告形式告知投资者吗？截至目前，KH815项目处于临床Ⅰ期阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100016410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0197","LU2148510915.USD","LU1064131003.USD","BK0196","002773","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638066257","title":"康弘药业：KH631、KH658已完Ⅱ期和Ⅰ期入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2638066257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638066257?lang=zh_cn&edition=full","pubTime":"2026-05-28 18:24","pubTimestamp":1779963858,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业05月28日在投资者关系平台上答复投资者关心的问题。投资者提问：据2025年8月机构调研，公司预计2026年上半年可取得KH631和KH658的I期全部受试者一年安全性完整数据，目前该数据尚未正式对外发布，请问公司何时发布一期及二期的全部安全性、有效性完整数据？截至目前，基因治疗平台的眼科项目KH631、KH658，均已完成了中国的临床Ⅱ期入组和美国的临床Ⅰ期入组，预计将于今年底进入中国临床Ⅲ期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800035588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","002773","BK0197","LU1064130708.USD","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637431801","title":"康弘药业（002773）披露二〇二五年度股东会决议公告，5月22日股价下跌1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637431801","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637431801?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:59","pubTimestamp":1779443953,"startTime":"0","endTime":"0","summary":"近日，成都康弘药业集团股份有限公司发布《二〇二五年度股东会决议公告》。公告显示，公司于2026年5月21日召开二〇二五年度股东会，会议采用现场与网络投票相结合方式举行，出席会议股东共283人，代表股份648,045,507股，占公司有表决权股份总数的70.3383%。所有议案均获通过，无否决议案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260522/32247302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","BK0239","BK0197","LU2148510915.USD","LU1064130708.USD","002773","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785754472111,"stockEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0948},{"period":"6month","weight":-0.2403},{"period":"1year","weight":-0.4559},{"period":"ytd","weight":-0.2561}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":-0.0681},{"period":"3month","weight":-0.0681},{"period":"6month","weight":-0.0694},{"period":"1year","weight":0.0725},{"period":"ytd","weight":-0.0344}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都康弘药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38200人(较上一季度增加1.33%)","perCapita":"17978股","listingDate":"2015-06-26","address":"四川省成都市金牛区蜀西路108号","registeredCapital":"92132万元","survey":" 成都康弘药业集团股份有限公司的主营业务是药品（包括生物制品、中成药、化学药）和医疗器械（主要是眼科医疗器械）的研发、生产与销售。公司的主要产品是中成药、化学药、生物药、医疗器械。公司2025年荣获“环保诚信企业”和“无废工厂”称号。","listedPrice":13.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康弘药业,002773,康弘药业股票,康弘药业股票老虎,康弘药业股票老虎国际,康弘药业行情,康弘药业股票行情,康弘药业股价,康弘药业股市,康弘药业股票价格,康弘药业股票交易,康弘药业股票购买,康弘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}